Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

This study has been completed.
Sponsor:
Information provided by:
National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:
NCT00086645
First received: July 7, 2004
Last updated: April 14, 2008
Last verified: April 2008

July 7, 2004
April 14, 2008
April 2004
Not Provided
Clinical Global Improvement [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00086645 on ClinicalTrials.gov Archive Site
  • Safety Monitoring Uniform Research Form (SMURF) [ Time Frame: post-baseline through week 12 ] [ Designated as safety issue: Yes ]
  • Children's Yale-Brown Obsessive-Compulsive Scale (CYBOCS) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Repetitive Behavior Scale-Revised (RBS-R) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Parent Chief Complaint [ Time Frame: Weeks 6 and 12 ] [ Designated as safety issue: No ]
  • Aberrant Behavior Checklist [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Child and Adolescent Symptom Inventory: Anxiety and Depression scales [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Behavioral Activation [ Time Frame: post-baseline through Week 12 ] [ Designated as safety issue: Yes ]
  • Caregiver Strain Questionnaire [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Vineland [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)
Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior

This study will determine the efficacy and safety of citalopram compared to placebo in the treatment of children with autism.

For children with autism spectrum disorders (ASD, also known as Pervasive Developmental Disorders - PDDs), repetitive behaviors are common and frequently interfere with functioning in the home as well as in social and educational settings. These behaviors may involve repetitive movements, rigid routines, repetitive play, and even repetitive speech. These behaviors may be associated with high levels of anxiety, severe tantrums. Self-injury can occur when these behaviors and routines are interrupted.

Participants will be randomly assigned to receive citalopram or placebo (administered as liquid), and carefully followed every two weeks. At the end of 12 weeks, children who have responded to treatment will be given the opportunity to continue in the study, with monthly visits, for an additional 24 weeks. Children who received placebo and did not respond to treatment at 12 weeks will be given the opportunity to receive a carefully monitored 12 week course of citalopram.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Autistic Disorder
Drug: citalopram
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
149
April 2007
Not Provided

Inclusion Criteria:

  • Able to walk
  • Diagnosis of Autistic Disorder, Asperger's Disorder, or PDD-NOS
  • Have a score greater than or equal to (>) 8 on the sum of items 1A, 2, 3 and 5 of the Compulsions Subscale of the Revised CYBOCS.
  • Have a rating of at least moderate behavioral disturbance based on the modified Clinical Global Impression-Severity of Illness score (CGI-S) at the time of screening (See description below).
  • Be free of psychotropic medication for at least one month for fluoxetine, two weeks for other SSRIs and neuroleptics, and for 5 days for stimulants prior to baseline ratings.
  • Be judged reliable for medication compliance and agree to keep appointments for study contacts and tests as outlined in the protocol (both subject and guardian(s)).

Exclusion Criteria:

  • Medical contraindications to therapy with SSRIs
  • Prior exposure to citalopram (or escitalopram) of sufficient dose or duration to determine response status
  • History of treatment failure to a clinically adequate trial of two select SSRIs
  • Diagnosis of Rett's Disorder or Childhood Disintegrative Disorder
  • Uncontrolled epilepsy, with a seizure within past 6 months
  • Child weighs less than (<) 15 kg at screening contact.
  • Pregnancy
  • Presence of chronic medical conditions that might interfere with study participation or where study participation would be contraindicated
  • Clinically significant abnormal baseline laboratory testing
  • History of bipolar disorder or manic episode induced by antidepressant exposure
  • Documented need for ongoing psychotropic medications besides study medication (with the exception of stable dose (at least 3 month) anti-convulsants for seizures).
  • Concomitant medication that would interfere with participation in the study.
  • Recent (< 2 months) initiation of behavior therapy (such as parent training, applied behavior analysis or behavior modification) in a clinic, with a private practitioner or in a school program. Participants who are in an established behavior therapy program (defined as greater than (>) 2 months for clinic or private practitioner or greater than (>) 1 month for school program) can be included in the study. Families will be asked not to initiate any new behavior therapy during the study.
Both
5 Years to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00086645
U54 MH66398, DDTR BD-DD
Yes
Not Provided
National Institute of Mental Health (NIMH)
Not Provided
Study Chair: Bryan King, MD University of Washington
National Institute of Mental Health (NIMH)
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP